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Abstract: Ovarian cancer is a leading killer of women, and no cure for advanced ovarian 
cancer is available. Alisertib (ALS), a selective Aurora kinase A (AURKA) inhibitor, has shown 
potent anticancer effects, and is under clinical investigation for the treatment of advanced solid 
tumor and hematologic malignancies. However, the role of ALS in the treatment of ovarian 
cancer remains unclear. This study investigated the effects of ALS on cell growth, apoptosis, 
autophagy, and epithelial to mesenchymal transition (EMT), and the underlying mechanisms in 
human epithelial ovarian cancer SKOV3 and OVCAR4 cells. Our docking study showed that 
ALS, MLN8054, and VX-680 preferentially bound to AURKA over AURKB via hydrogen bond 
formation, charge interaction, and π-π stacking. ALS had potent growth-inhibitory, proapop-
totic, proautophagic, and EMT-inhibitory effects on SKOV3 and OVCAR4 cells. ALS arrested 
SKOV3 and OVCAR4 cells in G
2
/M phase and induced mitochondria-mediated apoptosis and 
autophagy in both SKOV3 and OVCAR4 cell lines in a concentration-dependent manner. ALS 
suppressed phosphatidylinositol 3-kinase/protein kinase B (Akt)/mammalian target of rapamycin 
(mTOR) and p38 mitogen-activated protein kinase pathways but activated 5′-AMP-dependent 
kinase, as indicated by their altered phosphorylation, contributing to the proautophagic activity 
of ALS. Modulation of autophagy altered basal and ALS-induced apoptosis in SKOV3 and 
OVCAR4 cells. Further, ALS suppressed the EMT-like phenotype in both cell lines by restoring 
the balance between E-cadherin and N-cadherin. ALS downregulated sirtuin 1 and pre-B cell 
colony enhancing factor (PBEF/visfatin) expression levels and inhibited phosphorylation of 
AURKA in both cell lines. These findings indicate that ALS blocks the cell cycle by G
2
/M 
phase arrest and promotes cellular apoptosis and autophagy, but inhibits EMT via phosphati-
dylinositol 3-kinase/Akt/mTOR-mediated and sirtuin 1-mediated pathways in human epithelial 
ovarian cancer cells. Further studies are warranted to validate the efficacy and safety of ALS 
in the treatment of ovarian cancer. 
Keywords: alisertib, Aurora kinase A, epithelial ovarian cancer, cell cycle, apoptosis, autophagy, 
epithelial to mesenchymal transition, sirtuin 1
Introduction
Ovarian cancer is the eighth most common type of cancer and the seventh most common 
cause of cancer-related death in women worldwide, with 239,000 new cases and around 
152,000 deaths in 2012.1 In 2010, 19,959 women in the USA were diagnosed with ovar-
ian cancer, and 14,572 women in the USA died from the disease. In 2014, it is estimated 
that there will be 21,980 new cases of ovarian cancer and that an estimated 14,270 people 
will die of the disease in the USA.2 In Europe, there were around 65,600 new cases of 
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ovarian cancer and around 42,700 deaths due to the disease 
in 2012.1 In 2011, there were around 7,100 new cases of 
ovarian cancer diagnosed in the UK, and 4,300 women died 
from the disease.3 The estimated incidence of ovarian cancer 
is increasing among Chinese women; it has increased by 30% 
in the last 10 years and the mortality rate has increased by 
18%, with 15,000 deaths each year.1,4 Age and genetics are 
the most well established risk factors for ovarian cancer. The 
majority of women with epithelial ovarian cancer (EOC) are 
diagnosed at an advanced stage when the disease has spread 
beyond the ovary, which substantially increases the risk of 
recurrence and early death.5 Peritoneal dissemination and 
ascites are the major causes of patient morbidity and mortality. 
Platinum-based and taxane-based chemotherapy is standard 
of care for the first-line treatment of patients with advanced 
ovarian, fallopian tube, or peritoneal cancer.5 Responses are 
observed in up to ~80% of patients; however, 70%–80% of 
responding patients will relapse, requiring further systemic 
chemotherapy.6 The 5-year survival rate ranges from ~30% 
to 60%. Patients who relapse more than 6–12 months after 
completing platinum-based chemotherapy may respond again 
to platinum-based therapy, but repeated use of platinum agents 
can be limited due to acquired resistance or intolerance.6 
Hence, there is an urgent need to develop new, safe, and 
effective therapeutics for advanced EOC.
The Aurora kinases are a family of serine/threonine 
kinases consisting of three members, Aurora kinase A 
(AURKA), AURKB, and AURKC.7 The three members of 
the Aurora kinases of varying peptide lengths share similar 
catalytic domains located in the C-terminus, but their N-ter-
minal extensions are of variable length and display little or 
no similarity. AURKA and AURKB are essential regulators 
of mitosis and centrosome function and act by polymeriz-
ing microfilaments and controlling chromatid segregation, 
but the function of AURKC is less clear.7 All three Aurora 
kinases have a conserved adenosine triphosphate binding 
pocket but different amino acid sequences at the N-terminal 
domain. AURKA has critical roles in the regulation of 
mitotic entry, centrosome function, bipolar spindle assembly, 
and segregation of chromosomes.8,9 AURKA is critical for 
correct formation of the mitotic spindle. It is required for 
the recruitment of several different proteins important to 
spindle formation. Among these target proteins is TACC, a 
microtubule-associated protein that stabilizes centrosomal 
microtubules and kinesin 5, a motor protein involved in 
formation of the bipolar mitotic spindle.7
As a key regulator of the cell cycle, AURKA regulates 
G
2
/M transition. AURKA is regulated by phosphorylation 
in a cell cycle-dependent manner, occurring on a conserved 
residue, Thr288, within the activation loop of the catalytic 
domain of the kinase and resulting in a significant increase in 
enzymatic activity.10 Inhibition of AURKA expression leads 
to G
2
/M arrest and apoptosis, whereas ectopic expression 
allows cells to bypass the G
2
/M DNA damage checkpoint.11 
AURKA maps to human chromosome 20q13 and AURKB to 
17q13.1, which are loci frequently altered in human cancers. 
AURKC is located on chromosome 19q13.2 to 13.4, a region 
associated with loss of heterozygosity in ovarian cancer and 
pancreatic carcinomas. The expression and activity of Aurora 
kinases are tightly regulated, and dysregulation results in 
genetic instability, aneuploidy, and tumorigenesis.7,12 The 
AURKA gene is frequently amplified and/or overexpressed in 
a number of malignancies, including cancers of the bladder, 
breast, colon, liver, ovary, pancreas, stomach, and esophagus, 
and aberrant AURKA signaling is associated with malignant 
tumor behavior such as invasion and metastasis, advanced 
stage, and poor prognosis.11,13,14 Overexpression of AURKA 
is common in ovarian cancer, which is associated with super-
numerary centrosomes, a poor response to chemotherapy, 
and reduced overall survival.10,15–17
AURKA has become a target of interest for the treatment of 
cancer, and a number of Aurora kinase inhibitors that have dual 
specificity for AURKA and AURKB, including MK-0457 and 
PHA-739358, have been developed.11,14,18 Alisertib (MLN8237, 
ALS, Figure 1) is an investigational small-molecule inhibitor 
developed by Millennium Pharmaceuticals Inc (Boston, MA, 
USA) which selectively inhibits AURKA and has been shown 
in preclinical studies to induce cell cycle arrest, polyploidy, and 
mitotic catastrophe in various tumor cells, and to induce tumor 
regression in vivo.19–21 Currently, ALS is being tested in various 
Phase I and Phase II clinical trials for advanced solid tumors 
and hematologic malignancies.22–27 In the present study, we 
aimed to uncover the underlying mechanisms for the anticancer 
effects of ALS in human EOC cells. Before we performed 
our benchmarking experiments, we ran molecular docking 
assays to check how ALS bound to AURKA and AURKB 
and to compare the differences in the binding mode with 
those of other Aurora kinase inhibitors, including AMG-900, 
barasertib, CYC116, danusertib, MLN8054, and VX-680 
(also called MK-0457), which are selective or nonselective 
inhibitors for AURKA.11,28
Materials and methods
Molecular docking
In order to determine the molecular interactions between 
AURKA and AURKB and their inhibitors, the Discovery 
Drug Design, Development and Therapy 2015:9
Studio program 3.1 designed by Accelrys Inc (San Diego, 
CA, USA) was used to dock ALS, AMG-900 (a potent 
and highly selective pan-AURKA, AURKB, and AURKC 
inhibitor29), barasertib (a highly selective AURKB 
inhibitor30), CYC116 (a potent inhibitor of AURKA and 
AURKB31), danusertib (an AURKA, AURKB, and AURKC 
inhibitor31), MLN8054 (a potent and selective inhibitor of 
AURKA32), and VX-680 (a pan-AURKA, AURKB, and 
AURKC, mostly against AURKA33) (Figure 1) into the 
active sites of human AURKA (Protein Data Bank [PDB] 
identification [ID]: 2DWB) and AURKB (PDB ID: 4AF3) 
as previously described.34–36 The crystal structures of human 
AURKA and AURKB were obtained from the PDB (http://
www.rcsb.org/pdb/). The protein and ligand were prepared 
prior to the docking. For protein preparation, AURKA and 
AURKB were cleaned, modified, and prepared for defining 
and editing the binding site. During preparation for ALS, 
AMG-900, barasertib, CYC116, danusertib, MLN8054, and 
VX-680, the duplicate structures were deleted and ionization 
change, tautomer or isomer generation, Lipinski filter, and 
three-dimensional generator were all set true. A harmonic 
potential with the force constant of 300 kcal/mol was applied 
outside the grid boundary. Following preparation of pro-
tein, ligand, and grid setting, ALS, AMG-900, barasertib, 
CYC116, danusertib, MLN8054, and VX-680 were docked 
into binding sites of AURKA and AURKB. Electrostatic 
energy and van der Waals forces were considered during 
the docking process. For each defined van der Waals force 
or electrostatic probe, the interactions with all protein atoms 
were stored at predetermined grid points. For ligand atoms 
located between grid points, a trilinear interpolation was used 
to approximate the energies.
chemicals and reagents
ALS, Dulbecco’s phosphate-buffered saline (PBS), 
thiazolyl blue tetrazolium bromide (MTT), 4-(2-hydroxy-
ethyl)piperazine-1-ethanesulfonic acid (HEPES), ethylene-
diamine tetraacetic acid, RNase A, propidium iodide, and 
fetal bovine serum were purchased from Sigma-Aldrich Inc 
(St Louis, MO, USA). 4′ 6-Diamidino-2-phenylindole and 
5-(and 6)-chloromethyl-2′, 7′-dichlorodihydrofluorescein 
diacetate (CM-H
2
DCFDA) were sourced from Invitrogen 
(Carlsbad, CA, USA). Dulbecco’s Modified Eagle’s 
Medium and McCoy’s 5A medium were purchased from 
Corning Cellgro Inc (Herndon, VA, USA). The Annexin 
V:phycoerythrin apoptosis was purchased from BD Bio-
sciences Inc (San Jose, CA, USA). A Cyto-ID® autophagy 
detection kit was obtained from Enzo Life Sciences Inc 
(Farmingdale, NY, USA). The polyvinylidene difluoride 
membrane was sourced from Millipore Inc (Bedford, 
MA, USA). Western blotting substrate was obtained from 
Thermo Scientific Inc (Hudson, NH, USA). The autophagy 
inhibitors chloroquine, bafilomycin A, and wortmannin (an 
irreversible and selective  phosphatidylinositol 3-kinase 
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Figure 1 chemical structures of alisertib, aMg-900, barasertib, cYc116, danusertib, Mln8054, and VX-680, all of which are selective or pan inhibitors of aurora kinase 
a and aurora kinase B.
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[PI3K] inhibitor and a blocker of autophagosome forma-
tion), and the apoptosis inhibitor Z-VAD(OMe)-FMK 
were purchased from Invivogen (Carlsbad, CA, USA). 
SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-
5-(4-pyridyl) 1H-imidazole; an autophagy inducer and 
specific p38 mitogen-activated protein kinase inhibitor 
(MAPK)] was purchased from Santa Cruz Biotechnology 
Inc (Santa Cruz, CA, USA). Primary antibodies against 
human silent mating type information regulation 1 (sirtuin 1 
[Sirt1]), p53, acetylated (Ac)-p53 (Lys379), p21 Wafl/Cipl, 
p27 Kipl, cyclin B1, cell division cycle protein 2 homolog 
(CDC2), the p53-upregulated modulator of apoptosis 
(PUMA), B-cell lymphoma 2 (Bcl-2), Bcl-2-like protein4/
Bcl-2-associated X protein (Bax), B-cell lymphoma-extra-
large (Bcl-xl), cytochrome c, cleaved caspase 3, cleaved 
caspase 9, microtubule-associated protein 1A/1B-light 
chain 3 (LC3-I), LC3-II, p38 MAPK, phosphorylated 
(p)-38 MAPK at Thr180/Tyr182, protein kinase B (Akt), 
p-Akt at Ser473, mammalian target of rapamycin (mTOR), 
p-mTOR at Ser2448, PI3K, p-PI3K at Tyr458, 5′ AMP-
activated protein kinase (AMPK), p-AMPK at Thr172, 
beclin1, AURKA, p-AURKA at Thr288, and epithelial 
to mesenchymal transition (EMT) antibody sampler kit 
(#9782) were all purchased from Cell Signaling Technol-
ogy Inc (Beverly, MA, USA). The EMT antibody sampler 
kit contains primary antibodies to N-cadherin, E-cadherin, 
zona occludens protein 1 (ZO-1), vimentin, slug, snail, 
zinc finger E-box-binding homeobox 1 (TCF8/ZEB1), and 
β-catenin. The antibody against human β-actin and pre-B-
cell colony-enhancing factor (PBEF/visfatin, also called 
nicotinamide phosphoribosyltransferase) were obtained 
from Santa Cruz Biotechnology Inc.
cell lines and cell culture
SKOV3 and OVCAR4 cells are human EOC cell lines, and 
T80 cells are a normal epithelial ovarian cell line. SKOV3, 
OVCAR4, and T80 cells were obtained from the American 
Type Culture Collection (Manassas, VA, USA) and cultured 
in McCoy’s 5A medium. All medium contained L-glutamine, 
phenol red, L-cysteine, L-methionine, and sodium bicarbon-
ate, and was supplemented with 10% heat-inactivated fetal 
bovine serum. The cells were maintained at 37°C in a 5% 
CO
2
/95% air humidified incubator. ALS was dissolved in 
dimethyl sulfoxide (DMSO) with a stock concentration of 
50 mM, and was freshly diluted to the desired concentration 
with culture medium. The final concentration of DMSO was 
0.05% (v/v).
cell viability assay 
The MTT assay was performed to examine the effect of ALS 
on cell viability. Briefly, cells were seeded in 96-well culture 
plates at a density of 8×l03 per well. After the cells were 
attached, the medium was changed with freshly prepared 
medium containing ALS at different concentrations (from 
0.1 to 100 μM). The control cells received the vehicle only. 
After 24 hours of incubation, 10 μL MTT (5 g/L) was added 
to each well and cultured for another 4 hours. The medium 
was then removed and 150 μL of DMSO was added. It was 
shaken for 15 minutes for crystal dissolution. Absorbance 
at the 490 nm wavelength was measured with a Synergy H4 
Hybrid microplate reader (BioTek Inc, Winooski, VT, USA). 
IC
50
 values were determined using the relative viability over 
ALS concentration curve.
Cell cycle analysis using flow cytometry 
Propidium iodide is used as a DNA stain to determine DNA 
content in cell cycle analysis. The effect of ALS on cell 
cycle distribution was determined by flow cytometry as 
described previously.37 Briefly, SKOV3 and OVCAR4 cells 
were treated with ALS at different concentrations (0.1, 1, 
and 5 μM) for 24 hours. In separate experiments, SKOV3 
and OVCAR4 cells were treated with ALS 5 μM for 4, 8, 
12, 24, 48, or 72 hours. The cells were suspended, washed 
with PBS, centrifuged, and fixed in 70% ethanol at -20°C 
overnight. The cells were then resuspended in 1 mL of PBS 
containing 1 mg/mL RNase A and 50 μg/mL propidium 
iodide. The cells were incubated in the dark for 30 minutes 
at room temperature. In total, 1×104 cells were subject to cell 
cycle analysis using a flow cytometer (Becton Dickinson 
Immunocytometry Systems, San Jose, CA, USA).
simultaneous determination of apoptosis 
and autophagy using flow cytometry 
To explore the potential crosstalk between ALS-induced 
apoptosis and autophagy, we further determined the two 
modes of programmed cell death simultaneously. SKOV3 
and OVCAR4 cells were plated in six-well cell culture plates 
(Corning Incorporated, Corning, NY, USA) at a density of 
1×105 cells per well. After incubation overnight, the cells 
were incubated with fresh medium, vehicle alone (0.05% 
DMSO, v/v), or ALS at 0.1, 1, and 5 μM for 24 hours. For 
comparison purposes, the autophagy inducer SB203580 at 
10 μM, autophagy inhibitor wortmannin at 10 μM, chloro-
quine at 30 μM, bafilomycin A at 10 μM, and the apoptosis 
inhibitor Z-VAD(OMe)-FMK at 20 μM were used alone or 
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in combination with 5 μM ALS to treat the cells for 24 hours. 
At the end of treatment, the cells were trypsinized and centri-
fuged at 1,000× g for 5 minutes to pellet the cells. The cells 
were divided into two samples of equal volume and washed 
with PBS. For detection of apoptosis using Annexin V, each 
sample was resuspended in 1 mL of binding buffer (10 mM 
HEPES/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl
2
; fil-
tered through a 0.2 μm filter). An aliquot of cell suspension 
(195 μL) was mixed with 5 μL of Annexin-ATTO 647N 
(Enzo Life Sciences Inc; ALX-209-259-T100), and incubated 
for 10 minutes in the dark. The cells were washed once using 
PBS and resuspended in 190 μL of binding buffer; 10 μL of 
20 μg/mL propidium iodide was then added, and the cells 
were subjected to apoptotic analysis using flow cytometry. 
For detection of autophagy, each sample was washed by 
resuspending the cell pellet in 1× assay buffer (Enzo Life 
Sciences Inc; ENZ-51031-K200) and collected by centrifu-
gation. Cells were resuspended in 250 μL of phenol red-free 
culture medium (Invitrogen; #1294895) containing 5% fetal 
bovine serum, and 250 μL of diluted Cyto-ID green stain 
solution (Enzo Life Sciences Inc; #ENZ-51031-K200) was 
added to each sample and mixed well. Cells were incubated 
for 30 minutes at 37°C in the dark, collected by centrifuga-
tion, washed with 1× assay buffer, and resuspended in 500 
μL of fresh 1× assay buffer. Cells were analyzed using the 
green (FL1) channel of a flow cytometer.
Confocal fluorescence microscopy 
The cellular autophagy level was examined using a Cyto-ID 
autophagy detection kit according to the manufacturer’s 
instructions. The SKOV3 and OVCAR4 cells were seeded 
into an eight-well chamber slide at 30% confluence. After 
incubation overnight, the cells were treated with ALS 0.1, 
1, and 5 μM for 24 hours. In separate experiments, cells 
were pretreated with the autophagy inducer SB203580 
(10 μM), autophagy inhibitor wortmannin (10 μM), chloro-
quine (30 μM), bafilomycin A (10 μM), and the apoptosis 
inhibitor Z-VAD(OMe)-FMK (20 μM) for 1 hour, and then 
treated with ALS 5 μM. After incubation for 24 hours, the 
cells reached ~60% confluence, were washed three times 
with 1× assay buffer, and then fixed by paraformaldehyde. 
A 40 μL aliquot of assay buffer with 4′ 6-diamidino-2-
phenylindole was used to stain DNA molecules in the cells. 
The slides were covered with glass coverslips and sealed with 
polish oil. Samples were observed using a TCS SP2 laser 
scanning confocal microscope (Leica, Wetzlar, Germany) 
at a 405/488 nm wavelength.
Western blotting analysis 
Expression levels of the cellular proteins of interest were 
determined using Western blotting assays.37 SKOV3 and 
OVCAR4 cells were washed with pre-cold PBS after 
24 hours of treatment with ALS 0.1, 1, and 5 μM, lysed with 
radioimmunoprecipitation assay (RIPA) buffer (50 mmol 
HEPES at pH 7.5, 150 mmol NaCl, 10% glycerol, 1.5 mmol 
MgCl
2
, 1% Triton-X 100, 1 mmol ethylenediamine tet-
raacetic acid at pH 8.0, 10 mmol sodium pyrophosphate, 
10 mmol sodium fluoride) containing the protease inhibi-
tor and phosphatase inhibitor cocktails, and centrifuged at 
3,000× g for 10 minutes at 4°C. The protein concentrations 
were measured using a bicinchoninic acid protein assay kit 
(Pierce, Rockford, IL, USA). An equal amount of protein 
sample (30 μg) was resolved by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) sample 
loading buffer and electrophoresed on 7%−12% SDS-PAGE 
minigel after thermal denaturation at 95°C for 5 minutes. 
The proteins were transferred onto an Immobilon® polyvi-
nylidene difluoride membrane at 400 mA for 2 hours at 4°C. 
The membranes were probed with the primary antibodies 
indicated in the “Chemicals and reagents” section overnight 
at 4°C and then blotted with respective secondary antimouse 
or antirabbit antibody. Visualization was performed using a 
ChemiDoc™ XRS system (Bio-Rad, Hercules, CA, USA) 
with an enhanced chemiluminescence substrate, and the blots 
were analyzed using Image Lab 3.0 (BioRad). The protein 
level was normalized to the matching densitometry values 
of the internal control, β-actin.
statistical analysis
The data are presented as the mean ± standard deviation. Com-
parisons of multiple groups were evaluated by one-way analysis 
of variance followed by Tukey’s multiple comparison proce-
dure. P0.05 was considered to be statistically significant. 
Assays were performed at least three times independently.
Results
Molecular interactions between als and 
other inhibitors, and aUrKa and aUrKB
ALS is known to be a potent selective AURKA inhibitor with 
an IC
50
 of 1.2 nM, and also inhibits the activity of AURKB 
with an IC
50
 of 396.5 nM.21,38 To explore how ALS interacts 
with AURKA and AURKB and to compare the differences 
in molecular interactions between ALS and other Aurora 
kinase inhibitors, we first carried out docking experiments 
using the Discovery Studio program 3.1.
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The docking results are shown in Figures 2–4. After 
docking ALS into the active sites of AURKA and AURKB, 
there were one and 50 positions generated for ALS-
AURKA and ALS-AURKB interactions, respectively 
(Figures 2A and 3A). The CDOCKER interaction energy 
ranged from around -45 to 58 kcal/mol. Each compound-
enzyme complex with the highest CDOCKER interaction 
energy was selected, and two-dimensional and three- 
dimensional pictures of these complexes were collected. The 
data showed that ALS bound to AURKA through formation 
of a hydrogen bond at Lys258 and Cys290, a charge inter-
action at Lys258, and π-π stacking at Lys143 and Trp277 
(Figure 2A and Table 1). ALS also bound to AURKB via 
charge interaction at the site of His224 and π-π stacking at 
Figure 2 (Continued)
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Lys87 and Lys106 (Figure 3A). There was a remarkable 
difference in CDOCKER interaction energy for the interac-
tions between ALS and AURKA (-45.0219 kcal/mol) and 
AURKB (37.7089 kcal/mol), which may partly explain the 
difference in inhibitory effect of ALS on these two Aurora 
kinases. 
Further, we docked AMG-900, barasertib, CYC116, 
danusertib, MLN8054, and VX-680 into the active sites 
of AURKA and AURKB. There were one and 90 posi-
tions generated for AMG-900-AURKA and AMG-900-
AURKB interactions, respectively. AMG-900 interacted 
with AURKA via hydrogen bond formation at Lys143 and 
Leu289 and π-π stacking with Arg255, Lys258, and Trp277 
(Figure 2B). AMG-900 also bound to AURKB through π-π 
stacking at Lys85, Lys87, and Lys106 (Figure 3B). The 
CDOCKER interaction energy was 16.0013 kcal/mol and 
40.4091 kcal/mol for AMG-900-AURKA and AMG-900-
AURKB, respectively (Table 1). 
CYC116 bound to AURKA via charge interaction at 
Lys143 and π-π stacking at Arg255, Asp256, and Lys258, 
with a CDOCKER interaction energy of 25.4624 kcal/mol 
(Figure 2C and Table 1), and bound to AURKB through 
hydrogen bond formation at Asn205, charge interaction 
at Phe88, and π-π stacking at Lys87 and Lys106, with 
a CDOCKER interaction energy of 37.7216 kcal/mol 
(Figure 3C and Table 1). There were 360 positions for both 
CYC116-AURKA and CYC116-AURKB interactions. 
The MLN8054-AURKA interactions had 12 positions 
involving hydrogen bond formation at Ile257, charge 
interaction at Lys143, and π-π stacking at Arg255, Asp256, 
and Lys258 (Figure 2D), and the MLN8054-AURKB 
interactions had 50 positions involving hydrogen bond 
formation at Lys106 and π-π stacking at Lys87, Lys88, and 
Lys106 (Figure 4A). There was a marked difference in the 
CDOCKER interaction energy for the interactions between 
MLN8054 and AURKA (-113.729 kcal/mol) and AURKB 
Figure 2 Molecular docking of alisertib, aMg-900, barasertib, cYc116, danusertib, Mln8054, and VX-680 into the active site of human aUrKa (PDB iD: 2DWB).
Notes: alisertib (A), aMg-900 (B), cYc116 (C), Mln8054 (D), and VX-680 (E) were readily docked into the active site of aUrKa (PDB iD: 2DWB). There was no 
position generated for barasertib-aUrKa and danusertib-aUrKa interactions. 
Abbreviation: aUrKa, aurora kinase a; PDB, Protein Data Bank; iD, identity.
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Abbreviation: aUrKB, aurora kinase B; PDB, Protein Data Bank; iD, identity.
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(42.0608 kcal/mol; Table 1), which may explain the much 
higher binding affinity to AURKA. 
There were 18 and 400 positions produced for VX-680- 
AURKA and VX-680-AURKB interactions, respectively. 
VX-680 interacted with AURKA via hydrogen bond forma-
tion at Arg255 and Lys258 and via π-π stacking at Asp256 
and Trp277 (Figure 2E). VX-680 bound to AURKB through 
hydrogen bond formation at Lys106 and Phe219, charge 
interaction at Lys85 and Glu161, and π-π stacking at Lys87 
and Lys106 (Figure 4B). The CDOCKER interaction energy 
between VX-680-AURKA and VX-680-AURKB interac-
tions was markedly different, ie, -113.729 kcal/mol and 
35.1378 kcal/mol, respectively (Table 1). This marked dif-
ference in CDOCKER interaction energy may be associated 
with the preference of VX-680 toward AURKA.
Danusertib did not bind to AURKA and there was no 
position generated for the danusertib-AURKA interactions, 
whereas danusertib bound to AURKB with 158 positions 
via hydrogen bond formation at Lys106 and π-π stacking 
at Leu93, Lys87, and Lys106, with a CDOCKER interac-
tion energy of 49.8876 kcal/mol (Figure 3D). In addition, 
there was no position generated for the barasertib-AURKA/
AURKB interactions. Taken together, the docking results 
show that danusertib binds to AURKB, but not to AURKA, 
while barasertib does not bind to either AURKA or 
AURKB. 
als inhibits proliferation of sKOV3 
and OVcar4 cells
To determine whether ALS inhibited the proliferation of 
SKOV3 and OVCAR4 cells and whether ALS was toxic 
toward normal human epithelial ovarian (T80) cells, we 
first examined the effect of ALS on cell proliferation in the 
T80 cell line and in the SKOV3 and OVCAR4 EOC cell 
lines using the MTT assay. The concentration-dependent 
inhibitory effects of ALS on growth of T80, SKOV3, and 
OVCAR4 cells are shown in Figure 5. When T80 cells 
were treated with ALS at 0.1, 0.5, 2.5, 10, 25, and 100 
μM for 24 hours, the percentage cell viability over the 
control cells (100%) was 94.3%, 78.7%, 80.0%, 75.1%, 
59.5%, and 54.5%, respectively (Figure 5A). The percent-
age of live SKOV3 cells over the control cells (100%) was 
86.8%, 78.7%, 67.6%, 62.1%, 52.8%, and 28.3%, respec-
tively (Figure 5B). The percentage of live OVCAR4 cells 
over the control cells (100%) was 88.4%, 81.4%, 79.1%, 
59.2%, 53.0%, and 31.2%, respectively (Figure 5C). The 
IC
50
 values for ALS were 164.7 μM in T80 cells, 20.48 
μM in SKOV3 cells, and 22.13 μM in OVCAR4 cells. Ta
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Figure 5 effects of alisertib on proliferation of T80 (normal, A), sKOV3 (B), and OVcar4 (C) cells. cell viability was determined by the MTT assay. cells were treated with 
alisertib 0.1-100 μM for 24 hours and then subject to MTT incubation. ic50 values were determined. Data are shown as the mean ± standard deviation of three independent 
experiments. 
Abbreviation: als, alisertib; ic50, half maximal inhibitory concentration.
These results demonstrate that ALS induces a concentration-
dependent inhibitory effect on the growth of T80, SKOV3, 
and OVCAR4 cells, but the inhibitory effect on normal T80 
cells is significantly lower than the inhibitory effect on EOC 
cells. This suggests that ALS has no or low toxicity toward 
normal human ovarian epithelial cells.
als induces g2/M arrest, downregulates 
cyclin B1 and cDc2, and upregulates p27 
Kip1 and p53 in sKOV3 and OVcar4 cells 
We examined the effect of ALS on cell cycle distribution 
using a flow cytometer in both cell lines. ALS significantly 
induced G
2
/M phase arrest (Figure 6A). Compared with the 
control cells, the percentage of SKOV3 and OVCAR4 cells in 
G
2
/M phase were all increased in a concentration-dependent 
manner after treatment with ALS (Figures 6A and 6B). At 
basal levels, the percentage of SKOV3 and OVCAR4 cells 
in G
2
/M phase was 23.5% and 14.9%, respectively. When 
treated with ALS at 0.1, 1, and 5 μM for 24 hours, the per-
centage of SKOV3 cells was 51.9%, 86.5%, and 85.7%, 
respectively, and the percentage of OVCAR4 cells was 
33%, 87.9%, and 81.3%, respectively. We conducted further 
separate experiments to evaluate the effect of ALS 5 μM on 
cell cycle distribution in SKOV3 and OVCAR4 cells over 
72 hours (Figure 6C). Compared with control cells, the per-
centage of SKOV3 cells in G
2
/M phase was increased from 
6.11% at the basal level to 11.9%, 24.3%, 55.2%, and 88.1% 
after 4, 8, 12, and 24 hours of treatment with ALS 5 μM, and 
declined to 86.8% and 52.2% after 48 and 72 hours of treat-
ment with ALS 5 μM, respectively (Figure 6D). Similarly, 
compared with control cells, the percentage of OVCAR4 
cells in G
2
/M phase increased from 25.6% at the basal level 
to 31.5%, 44.7%, 53.7%, and 81.4% after 4, 8, 12, and 
24 hours of treatment with 5 μM ALS and declined to 79.0% 
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Figure 6 (A) effect of alisertib treatment for 24 hours on cell cycle distribution of sKOV3 and OVcar4 cells. cells were treated with alisertib 0.1, 1, and 5 μM for 24 hours 
and then subjected to flow cytometric analysis. (B) Bar graphs showing the percentage of sKOV3 and OVcar4 cells in g1, s, and g2/M phases. (C) Time course of alisertib-
induced cell cycle change over 72 hours in sKOV3 and OVcar4 cells. cells were treated with alisertib 5 μM for 4, 8, 12, 24, 48, and 72 hours and then subjected to flow 
cytometric analysis. (D) Bar graphs showing the percentage of sKOV3 and OVcar4 cells in g1, s, and g2/M phases. Data are shown as the mean ± standard deviation of 
three independent experiments. 
Abbreviations: als, alisertib; Pi, propidium iodide.
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and 19.3%, after 48 and 72 hours of treatment with 5 μM 
ALS, respectively (Figure 6D). 
On the contrary, treatment of SKOV3 and OVCAR4 
cells with ALS expressed a significantly reduced G
1
 phase 
at 0.1, 1, and 5 μM for 24 hours. The number of cells in G
1
 
phase was significantly reduced by 40.5%, 83.3%, and 82.5% 
when SKOV3 was treated in ALS for 24 hours. The number 
of OVCAR4 cells was also significantly reduced by 26.3%, 
91.3%, and 85.1% in G
1
 phase when treated with ALS for 24 
hours (Figure 6B). Similarly, there was a decrease in G
1
 phase 
when SKOV3 and OVCAR4 cells were treated with ALS 
5 μM for 72 hours. Compared with the control cells, the per-
centage of SKOV3 cells in G
1
 phase was decreased to 52.8%, 
82.2%, 92.3%, 94.4%, 89.3%, and 36.8% after 4, 8, 12, 24, 48, 
and 72 hours, respectively (Figures 6C and 6D). Compared 
with control cells, the percentages of OVCAR4 cells were 
decreased to 21.6%, 39.7%, 50.1%, 80.9%, 76.2%, and 36.8% 
after 4, 8, 12, 24, and 48 hours, respectively, and increased to 
15.7% after 72 hours of treatment with 5 μM ALS. 
In addition, compared with control cells, treatment of 
SKOV3 and OVCAR4 cells with ALS 0.1, 1, and 5 μM for 
24 hours significantly decreased the percentage of cells in 
S phase to 36.4%, 76.4%, and 79.8%, respectively, and to 
0.3%, 58.3%, and 45.7%, respectively (Figure 6B). Com-
pared with control cells, treatment of SKOV3 cells with 
ALS 5 μM for 4, 8, 12, 24, 48, and 72 hours increased 
the percentage of cells in S phase to 22.9%, 10%, 15.4%, 
13.4%, 1.3%, and 16.3%, respectively (Figure 6C), and in 
OVCAR4 cells, the percentage of cells in S phase increased 
to 37.9% and 20.8% at 4 and 8 hours and decreased to 
57.3%, 57.4%, and 14.6% at 24, 48, and 72 hours, respec-
tively (Figure 6C).
To explore the mechanism for the ALS-induced effects on 
cell cycle arrest in SKOV3 and OVCAR4 cells, the expres-
sion levels of key regulators responsible for G
2
 checkpoints 
were examined using the Western blotting assay (Figure 7A). 
Cyclin B1 and CDK1/CDC2 are two key regulators for the 
G
2
 to M phase transition,39 so their expression level was 
determined in SKOV3 and OVCAR4 cells. The expres-
sion of cyclin B1 was significantly suppressed in SKOV3 
and OVCAR4 cells treated with ALS 0.1, 1, and 5 μM for 
24 hours (P0.05 or P0.01). In comparison with control 
cells, the expression level of cyclin B1 in SKOV3 cells was 
decreased 61.7%, 83.7%, and 58.8% when treated with ALS 
0.1, 1, and 5 μM for 24 hours, respectively. The expression 
level of cyclin B1 in OVCAR4 cells was suppressed 15.6%, 
44.5%, and 61.7% when treated with ALS 0.1, 1, and 5 μM 
for 24 hours, respectively. There was a 19.9%, 29.1%, and 
44.6% reduction in the expression level of CDK1/CDC2 
in SKOV3 cells incubated with ALS 0.1, 1, and 5 μM for 
24 hours, respectively (P0.05 or P0.01). There was also 
a 19.1%, 43.7%, and 59.2% reduction in the expression level 
of CDK1/CDC2 in OVCAR4 cells incubated with ALS 0.1, 
1, and 5 μM for 24 hours, respectively (P0.05 or P0.01; 
Figure 7B). 
These results demonstrate that ALS can downregulate 
CDK1/CDC2 and cyclin B1 in SKOV3 and OVCAR4 cells 
with differential effects. This would contribute to cell cycle 
arrest in both cell lines when exposed to ALS. p21 Waf1/Cip1, 
p27 Kip1, and p53 in SKOV3 and OVCAR4 cells treated 
with ALS were determined using Western blotting assay. The 
tumor suppressor protein p21 Waf1/Cip1 acts as an inhibitor 
of cell cycle progression, and serves to inhibit kinase activity 
and block progression through G
1
/S in association with CDK2 
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Figure 7 effects of treatment with alisertib on expression levels of cDK1/cDc2, cyclin B1, p27 Kip1, and p53 in sKOV3 and OVcar4 cells.
Notes: (A) representative blots of cDK1/cDc2, cyclin B1, p27 Kip1, and p53 measured by Western blotting assay. sKOV3 and OVcar4 cells were treated with alisertib 
0.1, 1, and 5 μM for 24 hours, and β-actin was used as the internal control. (B) Bar graphs showing the relative levels of cDK1/cDc2, cyclin B1, p27 Kip1, and p53 in sKOV3 
and OVcar4 cells treated with alisertib 0.1, 1, and 5 μM for 24 hours. Data are shown as the mean ± standard deviation of three independent experiments. *P0.05, 
**P0.01, ***P0.001 by one-way analysis of variance. 
Abbreviations: als, alisertib; cDK1, cyclin-dependent kinase 1; cDc2, cell division cycle protein 2 homolog.
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complexes.40 During cell cycle stages when cell division cycle 
protein 2 homolog (CDC2)/cyclin B or cyclin-dependent 
kinase 2 (CDK2)/cyclin A is active, p53 is phosphorylated and 
upregulates p21 Waf1/Cip1 transcription via a p53-responsive 
element. p27 Kip1 is a member of the Cip/Kip family of 
cyclin-dependent kinase inhibitors.41 Like p57 Kip2 and p21 
Waf1/Cip1, p27 Kip1 enforces the G
1
 restriction point via its 
inhibitory binding to CDK2/cyclin E and other CDK/cyclin 
complexes.41 p53 is a tumor suppressor protein that plays a 
major role in the cellular response to DNA damage and other 
genomic aberrations.42 Activation of p53 can lead to either cell 
cycle arrest and DNA repair or apoptosis. p53 is phosphory-
lated at multiple sites and by several different protein kinases. 
DNA damage induces phosphorylation of p53 at Ser15 and 
Ser20, which leads to a reduced interaction between p53 and 
its negative regulator, mouse double minute 2 homologue.42 
As shown in Figure 7A, the expression level of p27 Kip1 was 
concentration-dependently increased in SKOV3 cells and 
OVCAR4 cells treated with ALS for 24 hours. In comparison 
with control cells, there was a 2.0-fold and 2.3-fold increase 
in expression of p27 Kip1 in SKOV3 cells treated with ALS 
at 1 and 5 μM for 24 hours (P0.05; Figure 7B), and a 
1.4-fold increase in expression of p27 Kip1 in SKOV3 cells 
treated with ALS at 0.1 μM for 24 hours. However, these 
changes were not statistically significant. When OVCAR4 
cells were treated with ALS 1 μM and 5 μM for 24 hours, 
the expression level of p27 Kip1 was increased 2.0-fold and 
2.3-fold, respectively (P0.05; Figure 7B). When OVCAR4 
cells were treated with ALS 0.1 μM for 24 hours, the expres-
sion of p27 Kip1 only increased 1.4-fold, but had no statistical 
significance in comparison with control cells. 
Moreover, there was a 1.5-fold increase in the expression 
level of p53 in SKOV3 cells treated with ALS 5 μM for 
24 hours (P0.05; Figure 7B). There was a 1.6-fold, 2.4-fold, 
and 3.9-fold increase in expression of p53 in OVCAR4 cells 
treated with ALS 0.1, 1, and 5 μM for 24 hours, respectively, 
compared with control cells (P0.05; Figure 7B). ALS did 
not affect the expression of p21 Waf1/Cip1 in SKOV3 and 
OVCAR4 cells.
als induces apoptosis of sKOV3 
and OVcar4 cells via activation of the 
mitochondria-dependent pathway
Flow cytometric analysis was used to examine the effect of 
ALS on apoptosis in SKOV3 and OVCAR4 cells. The num-
ber of apoptotic cells was first quantified and the results are 
shown in Figure 8A. The number of apoptotic cells at the basal 
level was 6.4% and was 6.2% in SKOV3 cells treated with 
the control vehicle only (0.05% DMSO, v/v). When SKOV3 
cells were treated with ALS 0.1, 1, and 5 μM for 24 hours, the 
total percentages of apoptotic cells (early and late apoptosis) 
were 9.8%, 9.0%, and 10.4%, respectively, with a 1.6-fold, 
1.4-fold, and 1.7-fold increase, respectively, compared with 
control cells. When treated with ALS 0.1 and 5 μM, the 
results showed a statistically significant difference (P0.05; 
Figure 8B). In OVCAR4 cells, the number of apoptotic cells 
was 4.5% at the basal level and 4.1% in cells treated with the 
control vehicle only (0.05% DMSO, v/v). When OVCAR4 
cells were treated with ALS 1 and 5 μM for 24 hours, the total 
percentage of apoptotic cells was increased 3.4-fold and 2.0-
fold compared with control cells (P0.05; Figure 8B).
The results of flow cytometric analysis clearly showed 
that ALS induced apoptotic cell death of both SKOV3 and 
OVCAR4 cells in a concentration-dependent manner. In 
order to elucidate the mechanism for the proapoptotic effect 
of ALS in SKOV3 and OVCAR4 cells, we first examined 
the effects of treatment with ALS on expression levels of the 
proapoptotic protein Bax and the antiapoptotic proteins Bcl-2 
and Bcl-xl (Figure 9A). In the mitochondrial/cytochrome 
c-mediated apoptotic pathway, various stimuli converge at 
the mitochondria and activate one or more members of the 
BH3-only protein family, which are tightly regulated by 
Bcl-2 family members. This promotes assembly of Bcl-2-
antagonist/killer-1 (Bak) and Bax oligomers within the 
outer membranes of the mitochondria, leading to release of 
cytochrome c into the cytosol, which in turn induces apop-
totic protease-activating factor-1 to generate apoptosome and 
activates caspase 9, and subsequently activates the down-
stream caspases 2, 3, 6–8, and 10.43 SKOV3 and OVCAR4 
cells were treated with ALS 0.1, 1, and 5 μM for 24 hours. 
The expression level of Bax was concentration-dependently 
increased in both cell lines (P0.05; Figures 9B and 9C). 
Incubation of SKOV3 cells with ALS 0.1, 1, and 5 μM 
significantly increased Bax expression (4.5-fold, 6.1-fold, 
and 6.3-fold, respectively, compared with control cells), and 
treatment of OVCAR4 cells with ALS 5 μM for 24 hours 
resulted in a remarkable increase in expression of Bax (2.0-
fold compared with control cells). In contrast, the expression 
level of Bcl-2 was decreased by 40.7% and by 51.7% in 
SKOV3 cells treated with ALS 1 and 5 μM, and by 27.9%, 
36.8%, and 47.6% in OVCAR4 cells treated with ALS at 
0.1, 1, and 5 μM, respectively (P0.05; Figures 9B and 9C). 
A significant increase in the expression level of Bax and 
reduction of Bcl-2 resulted in a significant decrease in 
the Bcl-2/Bax ratio in both cell lines, with a 6.7%, 6.6%, 
and 8.2% reduction in SKOV3 cells and a 25.7%, 27.8%, 
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Figure 9 effects of alisertib on expression levels of critical proapoptotic and antiapoptotic proteins in sKOV3 and OVcar4 cells.
Notes: (A) effect of treatment with alisertib on expression levels of Bcl-xl, Bax, Bcl-2, PUMa, cytochrome c, cleaved caspase 3, and cleaved caspase 9 in sKOV3 and 
OVcar4 cells determined using Western blotting assays. (B, C) Bar graphs showing relative levels of Bcl-xl, Bax, Bcl-2, PUMa, cytochrome c, cleaved caspase 3, and cleaved 
caspase 9 in sKOV3 and OVcar4 cells. β-actin was used as the internal control. Data are shown as the mean ± standard deviation of three independent experiments. 
*P0.05, **P0.01, ***P0.001 by one-way analysis of variance. 
Abbreviations: als, alisertib; PUMa, p53-upregulated modulator of apoptosis.
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and 24.2% reduction in OVCAR4 cells when treated 
with ALS 0.1, 1, and 5 μM for 24 hours, respectively 
(P0.01; Figures 9B and 9C). In addition, the expression 
level of Bcl-xl was suppressed after treatment with ALS 
5 μM in both cell lines in a concentration-dependent man-
ner. Compared with control cells, the expression level of 
Bcl-xl was reduced by 54.6% and 85.5% in SKOV3 and 
OVCAR4 cells, respectively, when treated with ALS 5 μM 
for 24 hours. The effect of ALS on expression of PUMA 
was also examined due to the important role of PUMA in the 
regulation of antiapoptotic proteins. Incubation of SKOV3 
and OVCAR4 cells with ALS increased the expression level 
of PUMA in a concentration-dependent manner. Treatment 
of SKOV3 cells with ALS 0.1, 1, and 5 μM for 24 hours sig-
nificantly increased the expression level of PUMA 2.4-fold, 
2.6-fold, and 4.1-fold (P0.05; Figure 9B), and treatment 
of OVCAR4 cells with ALS 1 and 5 μM for 24 hours sig-
nificantly increased the expression level of PUMA 1.6-fold 
and 1.8-fold, respectively (P0.05; Figure 9C).
The effect of treatment with ALS on the mitochondria-
related apoptotic pathway was further examined in SKOV3 
and OVCAR4 cells. The release of cytochrome c from the 
mitochondria into the cytosol initiates the caspase-dependent 
apoptotic cascade. The release of cytochrome c from the 
mitochondrial intermembrane space is the early event during 
apoptotic cell death.44 Upon apoptotic stimulation, cyto-
chrome c released from the mitochondria associates with pro-
caspase-9/Apaf 1 to form a complex that processes caspase 
9 from its inactive proenzyme to its active form, eventually 
triggering activation of caspase 3 and apoptosis.44 
We observed a significant increase in the activation of 
caspases 9 and 3 in SKOV3 and OVCAR4 cells treated with 
ALS. Compared with control cells, treatment of SKOV3 and 
OVCAR4 cells with ALS 0.1, 1, and 5 μM for 24 hours signifi-
cantly increased the level of cleaved caspase 3 and caspase 9. 
Treatment of SKOV3 cells with ALS 1 and 5 μM for 24 hours 
significantly increased the expression level of cleaved caspase 
3 by 3.9-fold and 5.0-fold, respectively, and treatment with 
ALS 5 μM increased the expression level of cleaved caspase 
9 by 2.7-fold (P0.01; Figure 9B). Treatment of OVCAR4 
cells with ALS 5 μM for 24 hours significantly increased the 
expression level of cleaved caspase 3 by 5.1-fold and treatment 
of OVCAR4 cells with ALS 0.1, 1, and 5 μM for 24 hours 
significantly increased the expression level of cleaved caspase 
9 by 1.3-fold, 1.5-fold, and 1.6-fold, respectively (P0.05; 
Figure 9C). These results indicate that ALS induced marked 
activation of caspase 9 and caspase 3 and eventually led to 
apoptotic death of both SKOV3 and OVCAR4 cells.
Further, we observed a significant increase in activation 
of cytochrome c in SKOV3 and OVCAR4 cells treated with 
ALS. Compared with control cells, treatment of SKOV3 
and OVCAR4 cells with ALS 1 and 5 μM for 24 hours sig-
nificantly increased the level of cytochrome c. Treatment of 
SKOV3 cells with ALS 1 and 5 μM for 24 hours significantly 
increased the expression level of cytochrome c 1.6-fold and 
2.0-fold, respectively (P0.05 and P0.01; Figure 9B), 
and treatment of OVCAR4 cells with ALS 1 and 5 μM 
increased the expression level of cytochrome c 1.0-fold and 
1.3-fold, respectively (P0.05 and P0.01; Figure 9C). 
als induces autophagy via inhibition of 
the Pi3K/akt/mTOr pathway in sKOV3 
and OVcar4 cells
After observing that ALS induced apoptosis in SKOV3 and 
OVCAR4 cells, we examined the effect of ALS on autophagy 
of SKOV3 and OVCAR4 cells using flow cytometric analysis 
and confocal microscopy (Figures 10 and 11). The percent 
of autophagic cells at the basal level was 5.0% and 4.43% 
for SKOV3 and OVCAR4 cells, respectively (Figure 10B). 
Incubation of SKOV3 and OVCAR4 cells with ALS for 
24 hours significantly increased the percentage of autophagic 
cells (Figure 10A). In SKOV3 cells, there was a 10.7-fold 
and 11.5-fold increase in the percentage of autophagic cells 
treated with ALS 0.1 and 1 μM for 24 hours compared with 
control cells (11.0% versus 1.0% and 11.9% versus 1.0%, 
respectively, P0.05; Figure 10B). When SKOV3 cells 
were treated with ALS 5 μM for 24 hours, the percentage 
of autophagic cells was only slightly increased compared 
with control cells, but the difference was not statistically 
significant (5.5% versus 1.0%, P0.05; Figure 10B). In 
addition, treatment of OVCAR4 cells with ALS 5 μM for 
24 hours resulted in a 3.24-fold increase in the percent-
age of autophagic cells (17.97% versus 5.53%; P0.001; 
Figure 10B). Treatment of OVCAR4 cells with ALS 0.1 and 1 
μM for 24 hours only slightly increased autophagic death.
We further confirmed the autophagy-inducing effects 
of ALS on SKOV3 and OVCAR4 cells using confocal 
microscopic examination (Figure 11A). In comparison with 
control cells, treatment with ALS caused an increase in 
autophagy in a concentration-dependent manner in SKOV3 
and OVCAR4 cells (Figure 11B). There was a 1.2-fold 
increase in autophagic death of SKOV3 cells when treated 
with ALS 1 μM for 24 hours, (P0.05; Figure 11B), but 
the lower concentration (0.1 μM) and higher concentration 
(5 μM) of ALS did not significantly affect autophagy of 
SKOV3 cells. For OVCAR4 cells, there was a 1.1-fold and 
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1.1-fold increase in autophagy when treated with ALS 1 and 
5 μM (P0.05; Figure 11B). A lower concentration of ALS 
(0.1 μM) did not significantly affect autophagy in OVCAR4 
cells. These results demonstrate that ALS induces autophagy 
in both SKOV3 and OVCAR4 cells. 
Next, we investigated the mechanisms for the autophagy-
inducing effect of ALS in SKOV3 and OVCAR4 cells. First, 
we examined the phosphorylation levels of PI3K at Tyr199 
and AMPK at Thr172; these are upstream signaling  molecules 
in the Akt/mTOR pathway and play an important role in 
regulation of cell proliferation and death.45 PI3K catalyzes the 
formation of phosphatidylinositol-3,4,5-triphosphate via phos-
phorylation of phosphatidylinositol, phosphatidylinositol- 
4-phosphate, and phosphatidylinositol-4,5 bisphosphate.46 
Growth factors and hormones trigger this phosphorylation 
event, which in turn coordinates cell growth, cell cycle, cell 
migration, and cell survival. In this study, ALS significantly 
inhibited phosphorylation of PI3K at Tyr199 in both cell lines 
in a concentration-dependent manner compared with control 
cells (Figure 12A). Exposure of SKOV3 and OVCAR4 
cells to ALS 0.1, 1, and 5 μM for 24 hours decreased the 
phosphorylation level of PI3K at Tyr199 (Figure 12B). 
However, incubation of each cell line with ALS did not 
significantly affect the expression level of total PI3K. The 
ratio of p-PI3K over PI3K was concentration-dependently 
decreased by ALS in both cell lines compared with control 
cells. In SKOV3 cells, the p-PI3K/PI3K ratio was decreased 
from 4.9 at the basal level to 3.5, 2.7, and 2.6 when SKOV3 
cells were treated with ALS 0.1, 1, and 5 μM, respectively 
(P0.05 or P0.01; Figure 12B). In OVCAR4 cells, ALS 
0.1, 1, and 5 μM decreased the ratio of p-PI3K/PI3K from 4.4 
at the basal level to 2.2, 1.0, and 2.9, respectively (P0.05 
or P0.01; Figure 12B).
AMPK is highly conserved from yeast to plants and ani-
mals and plays a key role in the regulation of energy homeo-
stasis, cell survival, and cell death.47 AMPK is a heterotrimeric 
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Figure 12 effects of alisertib on expression and phosphorylation levels of selected proautophagic and antiautophagic proteins, including Pi3K, aMPK, akt, mTOr, beclin 1, 
and lc3-ii in sKOV3 and OVcar4 cells. cells were treated with alisertib 0.1, 1, and 5 μM for 24 hours.
Notes: (A) representative blots of p-Pi3K and total Pi3K, p-aMPK and total aMPK, p-akt and total akt, p-mTOr and total mTOr, beclin 1, and lc3-ii in sKOV3 and 
OVcar4 cells treated with alisertib for 24 hours. (B) Bar graphs showing the levels of these proteins in sKOV3 and OVcar4 cells treated with alisertib for 24 hours. Data 
are shown as the mean ± standard deviation of three independent experiments. *P0.05, **P0.01, ***P0.001 by one-way analysis of variance. 
Abbreviations: als, alisertib; akt, protein kinase B; aMPK, activated 5′-aMP-dependent kinase; mTOr, mammalian target of rapamycin; phosphatidylinositol-4 
5-bisphosphate 3-kinase, phosphatidylinositol 3-kinase; lc3, microtubule-associated protein 1a/1B-light chain; p, phosphorylated.
complex composed of a catalytic α subunit and regulatory 
β and γ subunits. The kinase is activated by an elevated AMP/
adenosine triphosphate ratio due to cellular and environmental 
stress, such as heat shock, hypoxia, or ischemia. The tumor 
suppressor LKB1, in association with accessory proteins 
STRAD and MO25, phosphorylates AMPK at Thr172 in 
the activation loop, and this phosphorylation is required for 
AMPK activation. Under glucose starvation, AMPK promotes 
autophagy by directly activating Unc-51-like kinase 1 (ULK1, 
a homologue of yeast Atg1) through phosphorylation of Ser317 
and Ser777.48 Under nutrient sufficiency, high mTOR activity 
prevents ULK1 activation by phosphorylating ULK1 Ser757 
and disrupting the interaction between ULK1 and AMPK.48
ALS showed a promoting effect on phosphorylation of 
AMPK at Thr172 in both cell lines (Figure 12B). Incubation 
of SKOV3 cells with ALS for 24 hours activated phosphory-
lation of AMPK at Thr172 in a concentration-dependent man-
ner. In comparison with control cells, there was an increase 
in the AMPK phosphorylation level at Thr172 in SKOV3 
and OVCAR4 cells treated with ALS 0.1, 1, and 5 μM for 
24 hours (Figure 12B). However, there was no significant 
change in the expression of total AMPK compared with 
control cells. The ratio of p-AMPK over AMPK was con-
centration-dependently increased by ALS in both cell lines 
compared with control cells. In SKOV3 cells, the p-AMPK/
AMPK ratio was increased from 1.9 at the basal level to 2.7, 
3.5, and 4.3, when SKOV3 cells were treated with ALS 0.1, 1, 
and 5 μM, respectively (P0.05 or P0.01; Figure 12B). In 
OVCAR4 cells, ALS 0.1, 1, and 5 μM increased the ratio of 
p-AMPK/AMPK from 0.2 at the basal level to 0.7, 0.8, and 
1.3, respectively (P0.05 or P0.01; Figure 12B).
We examined further the regulatory effect of ALS on 
phosphorylation of Akt at Ser473 and mTOR at Ser2448 in 
SKOV3 and OVCAR4 cells (Figure 12A). Akt is involved 
in the regulation of various signaling downstream pathways, 
including metabolism, cell proliferation, survival, growth, 
and angiogenesis.49 As a downstream effector of PI3K, 
Akt can activate mTOR, while mTORC2 phosphorylates 
Akt at Ser473. Thus, stimulation of Akt phosphorylation at 
Thr308 by 3-phosphoinositide-dependent protein kinase-1 
leads to full Akt activation.49 mTOR plays a key role in cell 
growth, autophagic cell death, and homeostasis.50 mTOR is 
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phosphorylated at Ser2448 via the PI3 kinase/Akt signaling 
pathway and is autophosphorylated at Ser2481.50 mTOR 
inhibition promotes dissociation of mTOR from the complex 
of Atg13 with ULK1 and ULK2. The dissociation releases 
ULK1/2 to activate FIP200, a protein critical for autophago-
some formation and autophagy initiation.50 In comparison 
with control cells, the phosphorylation level of Akt at Ser473 
was decreased in SKOV3 and OVCAR4 cells on exposure to 
ALS 0.1, 1, and 5 μM for 24 hours, respectively (Figure 12B). 
However, there was no significant alteration in expression of 
Akt in either cell line (Figure 12B). However, the p-Akt/Akt 
ratio was significantly decreased in both cell lines treated with 
ALS. In SKOV3 cells, the p-Akt/Akt ratio was decreased 
from 3.3 at the basal level to 1.6, 0.7, and 0.9 when cells were 
treated with ALS 0.1, 1, and 5 μM for 24 hours, respectively. 
In OVCAR4 cells, the p-Akt/Akt ratio decreased from 1.14 
at the basal level to 0.5, 0.5, and 0.3 on exposure to ALS 0.1, 
1, and 5 μM, respectively (Figure 12B).
Exposure of SKOV3 and OVCAR4 cells to ALS 
5 μM resulted in a decrease in the phosphorylation level of 
mTOR at Ser2448 (Figure 12B). Treatment of SKOV3 and 
OVCAR4 cells with ALS 0.1 and 1 μM for 24 hours slightly 
reduced mTOR phosphorylation. There was no significant 
change in expression of total mTOR in either cell line 
when treated with ALS for 24 hours. Similarly, a decreased 
p-mTOR/mTOR ratio was observed in both cell lines when 
treated with ALS 5 μM (Figure 12B). In SKOV3 cells, the 
p-mTOR/mTOR ratio was decreased from 5.3 at the basal 
level to 2.9 when treated with ALS 5 μM (Figure 12B), 
but treatment of SKOV3 cells with ALS 0.1 and 1 μM for 
24 hours reduced mTOR phosphorylation by 5.2% and 4.2%, 
respectively; however, the difference did not reach statistical 
significance. In OVCAR4 cells, the p-mTOR/mTOR ratio 
decreased from 5.0 at the basal level to 2.7 on exposure to 
ALS 5 μM, (P0.05 or P0.01; Figure 12B). However, 
treatment of OVCAR4 cells with ALS 0.1 and 1 μM for 
24 hours reduced mTOR phosphorylation by only 3.5% and 
3.5%, respectively (P0.05).
Finally, we examined the effect of ALS on the expression 
levels of beclin 1 and LC3-I/II. Autophagy is tightly regu-
lated by beclin 1 (a mammalian homologue of yeast Atg6), 
which forms a complex with vacuolar sorting protein 34 
(Vps34, also called class III PI3K), and serves as a platform for 
recruitment of other Atgs that are critical for autophagosome 
formation.51,52 Upon initiation of autophagy, LC3 is cleaved 
at the C-terminus by Atg4 to form cytosolic LC3-I.53 LC3-I is 
consequently proteolytically cleaved and lipidated by Atg3 and 
Atg7 to form LC3-II, which localizes to the autophagosome 
membrane. Treatment of SKOV3 and OVCAR4 with ALS5 
μM for 24 hours significantly increased the expression of 
beclin 1 (Figure 12B). There was a 1.8-fold and 2.7-fold 
increase of beclin 1 in SKOV3 and OVCAR4 cells, respec-
tively, when treated with ALS 5 μM for 24 hours (P0.05; 
Figure 12B). However, treatment of SKOV3 and OVCAR4 
cells with ALS 0.1 and 1 μM for 24 hours increased beclin 1 
by 1.3-fold and 1.4-fold and by 1.5-fold and 1.8-fold, 
respectively, but none of these increases were statistically 
significant. 
After 24 hours of treatment with ALS, our Western blot-
ting analysis revealed two clear bands of LC3-I and LC3-II in 
SKOV3 and OVCAR4 cells (Figure 12A). LC3-II migrated 
more rapidly than LC3-I on SDS-PAGE, leading to the 
appearance of two bands after immunoblotting, ie, LC3-I with 
an apparent mobility of about 18 kDa and LC3-II with an 
apparent mobility of 16 kDa. In both SKOV3 and OVCAR4 
cells, there was a concentration-dependent increase in expres-
sion of LC3-II (Figure 12A). Compared with control cells, 
there was an increase in the LC3-II level in SKOV3 cells 
treated with ALS 5 μM for 24 hours and in the LC3-II level 
in OVCAR4 cells treated with ALS 1 and 5 μM for 24 hours, 
respectively. Treatment of SKOV3 and OVCAR4 cells with 
ALS had no significant effect on expression of LC3-I. How-
ever, the ratio of LC3-II to LC3-I was remarkably increased 
2.1-fold in SKOV3 cells treated by ALS 5 μM for 24 hours 
and was significantly increased 2.9-fold and 2.7-fold in 
OVCAR4 cells on exposure to ALS 1 and 5 μM, respectively 
(Figure 12B). These findings indicate that ALS had a strong 
autophagy-inducing effect on SKOV3 and OVCAR4 cells 
via inhibition of the PI3K/Akt/mTOR pathway.
als-induced apoptosis and autophagy 
crosstalk in sKOV3 and OVcar4 cells 
Flow cytometry and confocal fluorescence microscopy were 
used to evaluate the effect of inducers and inhibitors of 
autophagy on basal and ALS-induced apoptosis and autophagy 
in SKOV3 and OVCAR4 cells. Treatment of SKOV3 cells 
with SB203580 10 μM (a selective p38 inhibitor and 
autophagy inducer), bafilomycin A10 μM, wortmannin 10 μM 
(a PI3K inhibitor and autophagy blocker), Z-VAD(OMe)-
FMK (a pan-caspase inhibitor) 20 μM, and chloroquine (an 
autophagy inhibitor) 30 μM alone for 24 hours had no sig-
nificant effect on apoptosis of SKOV3 cells (Figure 13A). In 
addition, the above inducers and inhibitors coincubated with 
ALS5 μM; only wortmannin and Z-VAD(OMe)-FMK signifi-
cantly enhanced the apoptosis-inducing effect of ALS com-
pared with cells treated with ALS alone (12.3% versus 6.3% 
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Figure 13 effects of various inducers and inhibitors on apoptosis of sKOV3 and OVcar4 cells treated with alisertib 5 μM for 24 hours.
Notes: (A) Flow cytometric plots showing apoptosis of cells treated with alisertib ± the inducing or inhibiting compound. (B) Bar graphs showing apoptosis of cells treated 
with alisertib ± the inducing or inhibiting compound. Data are shown as the mean ± standard deviation of three independent experiments. *P0.05, ***P0.001 by one-way 
analysis of variance. 
Abbreviations: als, alisertib; DMsO, dimethyl sulfoxide; WM, wortmannin.
and 12.2% versus 6.3%, respectively, P0.05; Figure 13B). 
Others chemical regulators had no effect on apoptosis induced 
by ALS. In OVCAR4 cells, only Z-VAD(OMe)-FMK signifi-
cantly enhanced the apoptosis-inducing effect of ALS when 
compared with cells treated with ALS alone (21.9% versus 
5%, respectively, P0.001; Figure 13B).
Next, we evaluated the effect of induction or inhibition of 
autophagy on basal and ALS-induced autophagy in SKOV3 
and OVCAR4 cells (Figure 14A). In SKOV3 cells, treatment 
with ALS 5 μM slightly increased autophagy, but the dif-
ference was not statistically different. SKOV3 cells treated 
with SB203580 10 μM, wortmannin 10 μM, or chloroquine 
30 μM alone for 24 hours showed a 39.0-fold, 18.1-fold, 
and 18.5-fold increase in basal autophagy compared with 
control cells, respectively (P0.05 or P0.01; Figure 14B). 
SB203580 10 μM combined with ALS 5 μM increased 
ALS-induced autophagy by 10.9-fold. Wortmannin 10 μM 
coincubated with ALS 5 μM then increased autophagy 
5.7-fold, while chloroquine 30 μM and ALS 5 μM increased 
autophagy 6.8-fold compared with ALS 5 μM alone 
(P0.001; Figure 14B). Z-VAD(OMe)-FMK 20 μM and 
bafilomycin A 10 μM significantly decreased autophagy at 
the basal level, but when they were combined with ALS 5 μM, 
Z-VAD(OMe)-FMK 20 μM promoted a 2.6-fold increase of 
the autophagy induced by ALS compared with ALS 5 μM 
alone (P0.05; Figure 14B). However, bafilomycin A 
10 μM did not affect the ALS-induced autophagy effect.
In OVCAR4 cells, treatment with ALS 5 μM increased 
autophagy 4.3-fold (P0.05; Figure 14B). When OVCAR4 
cells were treated with SB203580 10 μM or wortmannin 
10 μM alone for 24 hours there was a 7.5-fold and 8.5-fold 
increase in basal autophagy compared with control cells, 
respectively (P0.05 or P0.01; Figure 14B). OVCAR4 cells 
treated with chloroquine 30 μM showed slightly increased 
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Figure 14 effects of various inducers and inhibitors on autophagy of sKOV3 and OVcar4 cells treated with alisertib 5 μM for 24 hours.
Notes: (A) Flow cytometric plots showing autophagy of cells treated with alisertib ± the inducing or inhibiting compound. (B) Bar graphs showing the autophagy of cells 
treated with alisertib ± the inducing or inhibiting compound. Data are shown as the mean ± standard deviation of three independent experiments. *P0.05, ***P0.001 by 
one-way analysis of variance. 
Abbreviations: als, alisertib; DMsO, dimethyl sulfoxide; WM, wortmannin.
autophagy, but the differences were not statistically significant 
(Figure 14B). SB203580 10 μM combined with ALS 5 μM 
increased autophagy 2.7-fold. Wortmannin 10 μM and ALS 
5 μM increased autophagy 2.9-fold (P0.001; Figure 14B), 
but chloroquine 30 μM with ALS 5 μM only increased 
autophagy 1.5-fold compared with ALS 5 μM alone (P0.05; 
Figure 14B). Z-VAD(OMe)-FMK 20 μM slightly increased 
autophagy by 2.2-fold compared with basal levels, and the 
difference was not statistically significant. However, when 
Z-VAD(OMe)-FMK 20 μM was combined with ALS 5 μM, 
the effect of autophagy increased to 2.4-fold compared with 
ALS 5 μM (P0.001; Figure 14B). Bafilomycin A 10 μM 
significantly decreased autophagy compared with basal levels; 
even when ALS 5 μM was combined, the effect of autophagy 
did not significantly increase (P0.05; Figure 14B).
We tested the effect of inducers and inhibitors of 
autophagy on basal and ALS-induced autophagy in SKOV3 
and OVCAR4 cells further, using confocal fluorescence 
microscopy (Figure 15A). In SKOV3 cells, we observed a 
significant increase in autophagy from the basal level when 
cells were treated with wortmannin 10 μM, which increased 
basal autophagy 2.0-fold; and chloroquine 30 μM, which 
increased the basal autophagy 1.6-fold. When wortmannin 
10 μM or chloroquine 30 μM was combined with ALS 5 μM, 
the autophagic effect was markedly enhanced. Compared 
with ALS alone, wortmannin 10 μM increased autophagy 
2.7-fold and chloroquine 30 μM increased it 1.9-fold 
(Figure 15B). Z-VAD(OMe)-FMK 20 μM did not affect 
basal autophagy, but increased ALS-induced autophagy 
2.2-fold (P0.05; Figure 15B). Treatment with bafilomycin 
A 10 μM reduced basal autophagy 3.9-fold and decreased 
ALS-induced autophagy 2.8-fold (P0.05; Figure 15B). 
In OVCAR4 cells, a similar effect of wortmannin 
10 μM increased autophagy 2.5-fold, and chloroquine 
30 μM increased autophagy 1.9-fold from basal levels 
(P0.001). Z-VAD(OMe)-FMK 20 μM did not affect basal 
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autophagy. Bafilomycin A 10 μM diminished the basal 
autophagy 2.7-fold (Figure 15B). When cotreated with ALS 
5 μM, autophagy was significantly increased in all groups. 
Wortmannin 10 μM increased ALS-induced autophagy 2.6-
fold, chloroquine 30 μM increased it 2.4-fold, Z-VAD(OMe)-
FMK 20 μM increased it 2.8-fold, and bafilomycin A 10 μM 
increased it 1.2-fold (Figure 15B).
als inhibits eMT in sKOV3 
and OVcar4 cells
EMT is a critical process involving the initiation, growth, 
invasion, and metastasis of cancer.54 EMT depends on a reduc-
tion in expression of cell adhesion molecules. E-cadherin is 
considered an active suppressor of invasion and growth of 
many epithelial cancers. Tight junctions, or zonula occludens, 
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form a continuous barrier to fluids across the epithelium and 
endothelium. They function in the regulation of paracellular 
permeability and in the maintenance of cell polarity, blocking 
the movement of transmembrane proteins between the apical 
and basolateral cell surfaces. Tight junctions are composed of 
claudin and occludin proteins, which join the junctions to the 
cytoskeleton. ZO-1, 2, and 3 are peripheral membrane adap-
tor proteins that link junctional transmembrane proteins such 
as occludin and claudin to the actin cytoskeleton.55 Herein, 
we examined the effect of treatment with on EMT-associated 
markers in SKOV3 and OVCAR4 cells using the Western 
blotting assay (Figure 16A).
Cadherins are a superfamily of transmembrane glyco-
proteins that contain cadherin repeats of approximately 
100 residues in their extracellular domain. They mediate 
calcium-dependent cell–cell adhesion, and the classic cad-
herin subfamily includes N-cadherin, P-cadherin, R-cadherin, 
B-cadherin, and E-cadherin. The cytoplasmic domain of clas-
sical cadherins interacts with β-catenin, γ-catenin, and p120 
catenin. Cancer cells often show upregulated N-cadherin in 
addition to loss of E-cadherin.55 As shown in Figure 16A, 
incubation of SKOV3 cells with ALS resulted in a concentra-
tion-dependent increase in the expression level of E- cadherin 
and a decrease in the expression level of N-cadherin. 
In SKOV3 cells, there was a 2.1-fold, 2.2-fold, and 1.9-fold 
increase in expression of E-cadherin when treated with ALS 
0.1, 1, and 5 μM for 24 hours, respectively, whereas ALS 
1 and 5 μM suppressed the expression level of N-cadherin 
1.8-fold and 2.8-fold, respectively (P0.05; Figure 16B). 
Consequently, with  increasing  concentrations of ALS, an 
increased ratio of E-cadherin over N-cadherin was observed. 
The E-cadherin/N-cadherin ratio was increased from 0.18 at 
the basal level to 0.5, 0.8, and 1.2 when SKOV3 cells were 
treated with ALS 0.1, 1, and 5 μM for 24 hours, respec-
tively (P0.05; Figure 16B). In OVCAR4 cells, there was 
a 2.7-fold and 3.5-fold increase in expression of E-cadherin 
when cells were treated with ALS 1 and 5 μM, respectively 
(Figure 16B). Meanwhile, ALS decreased the expression 
of N-cadherin 1.3-fold, 1.8-fold, and 5.8-fold, respectively, 
compared with control cells when OVCAR4 cells were 
treated with ALS 0.1, 1, and 5 μM for 24 hours, respectively. 
The E-cadherin/N-cadherin ratio was increased from 0.15 at 
the basal level to 0.5, 0.8, and 1.2 when OVCAR4 cells were 
treated with ALS 0.1, 1, and 5 μM for 24 hours, respectively 
(P0.05; Figure 16B). 
In order to examine the effect of ALS on EMT in SKOV3 
and OVCAR4 cells further, we tested the expression levels 
of several key regulators of E-cadherin (Figure 16B). Slug 
(a zinc finger transcriptional factor) together with TCF8/
ZEB1 are suppressors of E-cadherin in EMT.55 In addition, 
slug protects damaged cells from apoptosis by repressing 
P53-induced transcription of the proapoptotic Bcl-2 family 
protein, PUMA.55 ALS significantly reduced the expression 
level of slug in both cell lines (Figure 16B). In SKOV3 
cells, the expression level of slug was significantly sup-
pressed 1.9-fold and 3.1-fold when treated with ALS 1 and 
5 μM for 24 hours, respectively (P0.01; Figure 16B). In 
OVCAR4 cells, treatment with ALS 5 μM for 24 hours, 
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Figure 16 effect of alisertib on expression levels of selected epithelial to mesenchymal transition markers in sKOV3 and OVcar4 cells.
Notes: (A) representative blots showing levels of e-cadherin, n-cadherin, slug, TcF-8/ZeB1, vimentin, β-catenin, claudin-1, and ZO-1 in sKOV3 and OVcar4 cells treated 
with alisertib 0.1, 1, and 5 μM for 24 hours determined by Western blotting assay. (B) Bar graphs showing levels of e-cadherin, n-cadherin, slug, TcF-8/ZeB1, vimentin, 
β-catenin, claudin-1, and ZO-1 in sKOV3 and OVcar4 cells treated with alisertib 0.1, 1, and 5 μM over 24 hours. β-actin was used as the internal control. Data are shown 
as the mean ± standard deviation of three independent experiments. *P0.05; **P0.01; ***P0.001 by one-way analysis of variance. 
Abbreviation: ALS, alisertib; TCF8, transcription factor 8; ZEB1, zinc finger E-box binding homeobox 1; ZO-1, zona occludens 1.
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respectively significantly reduced the expression level of slug 
by 2.1-fold (P0.05; Figure 16B). Further, ALS induced a 
concentration-dependent reduction in the expression level 
of TCF-8/ZEB1 in SKOV3 and OVCAR4 cells. In SKOV3 
cells, ALS 0.1, 1, and 5 μM significantly suppressed the 
expression level of TCF-8/ZEB1 by 1.4-fold, 1.7-fold, and 
2.4-fold, respectively (P0.05; Figure 16B). Similarly, 
there was a 1.8-fold, 2.4-fold, and 2.3-fold reduction in the 
expression of TCF-8/ZEB1 in OVCAR4 cells treated with 
ALS 0.1, 1, and 5 μM, respectively (P0.001; Figure 16B). 
Vimentin is a type III intermediate filament protein that is 
expressed in mesenchymal cells.55 β-catenin can act as an 
integral component of a protein complex in adherens junc-
tions, helps cells maintain epithelial layers, and participates 
in the Wnt signaling pathway as a downstream target.55 Treat-
ment of cells with ALS 1 and 5 μM significantly suppressed 
the expression level of vimentin by 2.8-fold and 7.4-fold in 
SKOV3 cells (P0.05; Figure 16B). ALS 0.1 μM reduced 
the vimentin level by 1.4-fold, but this change was not sta-
tistically significant. In OVCAR4 cells, treatment with ALS 
0.1, 1, and 5 μM for 24 hours resulted in a 1.4-fold, 1.6-fold, 
and 2.0-fold reduction in vimentin expression levels, but 
these changes were not statistically significant (Figure 16B). 
There was a significant reduction in the expression level of 
β-catenin in both cell lines treated with ALS 0.1, 1, and 5 
μM for 24 hours. ALS 1 and 5 μM significantly decreased 
the expression level of β-catenin by 1.4-fold and 2.6-fold in 
SKOV3 cells, and by 2.0-fold and 2.8-fold in OVCAR4 cells, 
respectively (Figure 16B). 
Finally, expression of ZO-1 was examined in SKOV3 
and OVCAR4 cells exposed to ALS. ZO-1 and ZO-2 are 
required for the formation and function of tight junctions. 
In subconfluent proliferating cells, ZO-1 and ZO-2 have 
been shown to colocalize to the nucleus and play a role in 
transcriptional regulation, possibly by facilitating nuclear 
import/export of transcriptional regulators.55 A significant 
effect of ALS on the expression of ZO-1 was observed in both 
cell lines (Figure 16A). Treatment of SKOV3 cells with ALS 
0.1, 1, and 5 μM for 24 hours increased 6.4-fold, 6.7-fold, 
and 10.3-fold in the expression of ZO-1 and 1 and 5 μM ALS 
resulted in a 7.1-fold and 9.7-fold increase in the expression 
level of ZO-1 in OVCAR4 cells (P0.05; Figure 16B).
sirt1 plays a role in als-induced 
autophagy and eMT inhibition in sKOV3 
and OVcar4 cells
Sirt1 plays an important role in the regulation of cellu-
lar autophagy through two major mechanisms. Sirt1 can 
 influence autophagy directly via its deacetylation of key com-
ponents of the autophagy induction network, such as Atgs 5, 
7, and 8. Nucleus-localized Sirt1 is also known to induce the 
expression of components of the autophagy pathway via acti-
vation of members of the FoxO transcription factor family.56 
Therefore, we speculated that ALS may regulate expression 
of Sirt1 in SKOV3 and OVCAR4 cells and examined the 
effect of ALS on the expression level of Sirt1 in both cell 
lines. As shown in Figure 17A, there was a concentration-
dependent reduction in the expression of Sirt1 in SKOV3 and 
OVCAR4 cells. Incubation of SKOV3 cells with ALS 1 and 
5 μM for 24 hours reduced the expression of Sirt1 by 58.9% 
and 64.1%, respectively; in OVCAR4 cells, treatment with 
ALS 5 μM for 24 hours significantly suppressed the expres-
sion level of Sirt1 by 69.5% (Figure 17B).
To further verify the expression of Sirt1, we extracted 
cytoplasmic protein and nuclear protein from SKOV3 and 
OVCAR4 cells treated with ALS 0.1, 1, and 5 μM. In the 
nuclear protein of SKOV3, exposure to ALS 1 and 5 μM 
for 24 hours reduced the expression of Sirt1 by 46.6% and 
56.9%, respectively (Figure 17B). However, in the cytosol 
of SKOV3, expression of Sirt1 was not significantly differ-
ent. In OVCAR4 cells, expression of Sirt1 was significantly 
decreased in both the nucleus and cytosol. In the nucleus, 
expression of Sirt1 was suppressed by 47.1%, 55.7%, and 
74.5% when OVCAR4 cells were treated with ALS 0.1, 1, 
and 5 μM, respectively; in the cytosol, expression of Sirt1 was 
suppressed by 45.8% and 48.5% when these cells were treated 
with ALS 1 and 5 μM, respectively (P0.05; Figure 17B). 
Downregulation of Sirt1 by ALS may partially contribute to 
ALS’ autophagy-inducing and EMT-inhibitory effects.
als inhibits phosphorylation of aUrKa 
in sKOV3 and OVcar4 cells 
To verify further the anticancer effect of ALS on the treat-
ment of EOC by suppressing AURKA, we investigated the 
expression of AURKA and phosphorylated AURKA in 
SKOV3 and OVCAR4 cell lines exposed to ALS. When 
SKOV3 cells were treated with ALS 0.1 and 5 μM for 24 
hours, expression of AURKA increased 1.8-fold and 1.9-
fold, respectively (P0.05; Figure 18B). Expression of 
p-AURKA increased 1.1-fold, 0.9-fold, and 1.4-fold when 
SKOV3 cells were treated with ALS 0.1, 1, and 5 μM for 
24 hours, respectively, but these changes were not statisti-
cally significant. However, the p-AURKA/AURKA ratio 
was suppressed by 49.2%, 48.5%, and 40.8% when SKOV3 
cells were treated with ALS 0.1, 1, and 5 μM, respectively 
(P0.01 or P0.05; Figure 18B).
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Figure 17 sirt1 plays a role in alisertib-induced apoptosis, autophagy, and eMT inhibition in sKOV3 and OVcar4 cells.
Notes: (A) alisertib downregulates sirt1 and PBeF/visfatin and upregulates ac-p53 in sKOV3 and OVcar4 cells as shown by Western blotting assay. cells were treated 
with alisertib 0.1, 1, and 5 μM for 24 hours. (B) Bar graphs showing relative expression levels of sirt1, PBeF/visfatin, and ac-p53 in sKOV3 and OVcar4 cells. Data are shown 
as the mean ± standard deviation of three independent experiments. *P0.05, **P0.01, ***P0.001 by one-way analysis of variance. 
Abbreviations: ac, acetylated; als, alisertib; PBeF, pre-B cell colony enhancing factor; sirt1, sirtuin 1; nucl, nuclear; cyto, cytosolic.
In OVCAR4 cells, expression of AURKA decreased 
significantly by 63.9% when these cells were treated 
with ALS 5 μM for 24 hours (Figure 18B). There was no 
statistically significant difference in AURKA expression 
when OVCAR4 cells were treated with ALS 0.1 or 1 μM 
for 24 hours. Similarly, expression of p-AURKA and the 
ratio of p-AURKA/AURKA were not significantly different 
when OVCAR4 cells were treated with different concentra-
tions of ALS.
Discussion
Treatment of advanced ovarian cancer remains a major 
challenge because of the poor efficacy of current therapies 
and chemotherapy. Despite novel therapeutic advances, 
improvement in the survival rate of patients with EOC 
has been marginal, suggesting the presence of unique, 
active, intrinsic mechanisms that impart resistance to che-
motherapeutic agents in EOC. Recently, there has been 
an increased interest in seeking new effective drugs for 
EOC from new compounds. AURKA is expressed in late 
S phase, peaking at G
2
/M phase and declining at G
1
 phase, 
and is involved in centrosome maturation and separation, 
bipolar spindle assembly, and mitotic entry. AURKB, 
known as the chromosomal passenger protein, is essential 
for accurate chromosome segregation and cytokinesis,57 
and AURKC complements the function of AURKB, which 
is expressed in the testes.58 With more and more studies 
focusing on the effect of the Aurora kinases in formation 
of solid tumors, AURKA has become more important in 
cancer therapy. Both overexpression and gene amplifica-
tion of AURKA have been characterized in human tumors, 
and have been shown to correlate with tumor proliferation 
rates and prognostic markers.59 Recent reports suggest 
that AURKA can induce chemotherapeutic resistance and 
regulate several key signaling pathways related to the cell 
cycle, apoptosis, autophagy, and EMT 8,59,60 in cancer cells, 
suggesting AURKA’s role as a central node in cancer cell 
signaling.61 With the goal of exploiting this pathway in 
anticancer therapy, we evaluated the impact of the AURKA 
inhibitor ALS on EOC cells. Based on our docking studies, 
ALS, MLN8054, and VX-680 showed a binding prefer-
ence for AURKA mainly via hydrogen bond formation, 
charge interactions, and π-π stacking interactions, which 
are all known AURKA inhibitors. Other compounds 
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Figure 18 effects of alisertib on expression and phosphorylation levels of aUrKa in sKOV3 and OVcar4 cells. cells were treated with alisertib 0.1, 1, and 5 μM for 
24 hours and expression levels of p-aUrKa and total aUrKa were determined using Western blotting assay.
Notes: (A) representative blots showing the intensities of p-aUrKa and total aUrKa in cells. (B) Bar graphs showing the levels of p-aUrKa and total aUrKa in sKOV3 
and OVcar4 cells. Data are shown as the mean ± standard deviation of three independent experiments. *P0.05, **P0.01 by one-way analysis of variance. 
Abbreviations: als, alisertib; aUrKa, aurora kinase a; p, phosphorylated.
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including AMG-900, CYC116, and danusertib could all 
bind to AURKA or AURKB with higher binding energy. 
ALS,38 AMG-900,29 barasertib,30 CYC116,31 danusertib,31 
MLN8054,32 and VX-68033 are all known inhibitors of 
Aurora kinases with distinct binding affinity and preference. 
ALS is a selective AURKA inhibitor with an IC
50
 of 1.2 nM. 
For AURKB, the IC
50
 value is more than 200-fold higher 
than that of AURKA.38 MLN8054 is a potent and selective 
inhibitor of AURKA, with an IC
50
 of 4 nM. It is more than 
40-fold selective for AURKA over AURKB.32 In addition, 
VX-680 is a pan-Aurora kinase inhibitor, mostly targeting 
AURKA, with an IC
50 
of 0.6 nM. VX-680 is less potent to 
AURKB and AURKC, with IC
50
 values of 18 nM and 4.6 
nM, respectively.33 Our docking results showed that ALS, 
MLN8045, and VX-680 docked easily into the active site 
of AURKA and with low CDOCKER interaction energy 
when compared with their interactions with AURKB. The 
docking results show that the low CDOCKER interaction 
energy may explain their high potency and preference for 
AURKA over AURKB. 
The Aurora kinases are related to the AGC (protein 
kinase A, protein kinase G, and protein kinase C) branch 
of the protein kinases. Part of the activation mechanism for 
most AGC kinases is mediated by binding of the phosphory-
lated C-terminal “hydrophobic motif”, FXXF(T/S)F, to the 
N-terminal lobe of the kinase catalytic domain.9,58 However, 
Aurora kinases lack canonical C-terminal hydrophobic motifs 
and are activated in trans through binding of regulatory 
proteins to their N-terminal lobe. The catalytic domain of 
AURKA has the typical bilobal kinase fold, comprised of an 
N-terminal β-strand domain (residues 127–215) and a C-ter-
minal α-helical domain (residues 216–385).62 These domains 
are linked together by a hinge region (residues 210–216) that 
plays an important part in forming the catalytic active site. 
Residues 273–292 are located at the N-terminal end of the 
activation loop of AURKA which adopt a unique conforma-
tion. Trp277 in the activation loop is stabilized by interactions 
with residue Phe144 in the flexible glycine-rich loop and resi-
due Phe275.62 Trp277 in AURKA corresponds to Phe187 in 
cAMP-dependent kinase and Leu407 in SRC proto-oncogene 
kinase, which is conserved in all three human Aurora kinases 
and all known Aurora-like sequences. In our docking study, 
we observed that Trp277 bound to ALS, VX-680, and AMG-
900, indicating the important role of Trp277 in ligand binding. 
Notably, Lys87 and Lys106 in AURKB bind to ALS, AMG-
900, danusertib, MLN8054, and VX-68 via hydrogen bond 
formation and/or π-π stacking, suggesting their important 
role in ligand binding of AURKB.
Next, we explored the effects of ALS on growth, 
proliferation, apoptosis, and autophagy in SKOV3 and 
OVCAR4 cells. We observed a potent inhibitory effect of 
ALS on cell proliferation in the two EOC cell lines. We 
found that ALS promoted cell apoptosis and autophagy, 
and induced cell cycle arrest in SKOV3 and OVCAR4 cells. 
Further, we observed that ALS inhibited EMT (Figure 16) in 
both cell lines and Sirt1 was involved in the inhibitory effects 
of ALS on the growth of EOC cells (Figure 17).
Recent studies indicate that AURKA may enable cancer 
cells to become chemoresistant and radioresistant through 
dysregulation of cell cycle progression and the DNA damage 
response. Direct evidence suggests that AURKA inhibits 
p53, p21 Waf1/Cip1, and p27 Kip1, but enhances cyclin 
B1 to repeal cell cycle checkpoints and to promote cell 
cycle progression.63 In previous studies, the effect of ALS 
on cell cycle distribution has been confirmed in various 
cancer cell lines.59 In the present study, we found that 
ALS arrested SKOV3 and OVCAR4 cells in G
2
/M phase 
in a concentration-dependent and time-dependent manner 
(Figure 6). We further explored the effect of ALS on key 
regulators of cell cycle checkpoints, including CDC2 and 
cyclin B1, in both cell lines. The CDC2-cyclin B1 complex 
is vital in regulation of the G
2
/M phase transition and mitosis. 
We observed a significant decrease in the expression level of 
cyclin B1 and CDC2 in SKOV3 and OVCAR4 cells treated 
with ALS, providing an explanation for the effect of ALS on 
G
2
/M phase arrest in SKOV3 and OVCAR4 cells (Figure 7). 
It has been reported that p27 Kip1, a cyclin-dependent kinase 
inhibitor regulated by p53, can bind to the CDK1/CDC2-
cyclin B1 complex, thereby inducing cell cycle arrest.63 We 
observed that expression of p53 and p27 Kip1 was increased 
in a concentration-dependent and time-dependent manner 
in SKOV3 and OVCAR4 cells treated with ALS, which 
probably contributes to the inhibitory effect of ALS on cell 
proliferation and its inducing effect on cell cycle arrest in 
SKOV3 and OVCAR4 cells (Figure 7). 
Programmed cell death, referring to apoptosis, autophagy, 
and programmed necrosis, is proposed to be death of a cell 
in any pathological format when mediated by an intracel-
lular program. These three forms of programmed cell death 
may jointly decide the fate of malignant neoplastic cells; 
apoptosis and programmed necrosis invariably contribute to 
cell death, whereas autophagy can have either prosurvival 
or prodeath roles.64 
Apoptosis, or type I programmed cell death, is character-
ized by specific morphological and biochemical changes of 
dying cells, including cell shrinkage, nuclear condensation 
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and fragmentation, dynamic membrane blebbing, and loss of 
adhesion to neighboring cells or to the extracellular matrix. 
Biochemical changes include chromosomal DNA cleavage 
into internucleosomal fragments, phosphatidylserine exter-
nalization, and a number of intracellular substrate cleavages 
by specific proteolysis.64 Apoptosis is executed by members 
of the caspase family of cysteine proteases, which can be 
activated by two main pathways, ie, the extrinsic death 
receptor pathway and the intrinsic mitochondria/cytochrome 
c-mediated pathway. The two pathways are linked and both 
trigger the activation of caspases 3, 6, and 7. In the death 
receptor pathway, binding of extracellular death ligands 
to members of the tumor necrosis factor and nerve growth 
factor receptor superfamily induces activation of caspase 8, 
which in turn activates caspases 3 and 7, resulting in further 
caspase activation events and finally cell death.65,66 It has 
been reported that suppression of AURKA increased apop-
tosis of small cell lung cancer cells. A potential mechanism 
for the increase of apoptosis is the downregulation of Bcl-2 
and upregulation of Bax.67 Another study indicated AURKA 
plays a crucial role in growth by inhibiting cell apoptosis and 
propelling cell cycle.8 The proapoptotic effect of ALS has 
been reported in various cancer cell lines, including Burkitt 
lymphoma, breast cancer, melanoma, and leukemia.68–70 In 
the present study, we observed concentration-dependent 
ALS-induced apoptosis in SKOV3 and OVCAR4 cells 
(Figure 8). It is known that mitochondrial disruption and 
the subsequent release of cytochrome c initiate the pro-
cess of apoptosis.66 The release of cytochrome c from the 
mitochondria was initiated by proapoptotic members of the 
Bcl-2 family but antagonized by antiapoptotic members 
of this family. Antiapoptotic members of the Bcl-2 family 
can be inhibited by post-translational modification and/or 
by increased expression of PUMA, which is an essential 
regulator of p53-mediated cell apoptosis.66 In addition, the 
cytosolic cytochrome c released from the mitochondria fol-
lowing an apoptotic stimulus serves as a main trigger for 
caspase enzyme activation.66 In our study, we found that the 
cytosolic level of cytochrome c was significantly increased 
after treatment with ALS, which subsequently activated 
caspase 9. Activated caspase 9 in turn activated caspase 3. 
Activated caspase 3 ultimately induced apoptosis, with a 
decrease in the Bcl-2 level (Figure 9). Moreover, we noted 
a concentration-dependent increase in expression of PUMA 
in SKOV3 and OVCAR4 cells. These results indicate that 
ALS induces mitochondria-dependent apoptosis in both 
SKOV3 and OVCAR4 cells, with the involvement of p53 
(Figure 9).
Autophagy (also known as type II programmed cell 
death), the process of degradation of unwanted or damaged 
cell elements, is extremely important for a variety of human 
diseases, especially cancers. This process influences vari-
ous stages of initiation and progression of cancer, which is 
caused by overlapping signaling pathways of autophagy and 
carcinogenesis. However, due to the complexity of cancer as 
a systemic disease, the fate of tumor cells is not determined 
by one signaling pathway.71 Recently, the PI3K/AKT/mTOR 
signaling pathway has come to be regarded as the key regula-
tor of a series of cell processes, as it can be deregulated by 
various genetic and epigenetic mechanisms in a wide range 
of cancer cells.64 PI3K activates the serine/threonine kinase 
Akt, which, in turn, through a cascade of regulators, results 
in phosphorylation and activation of the serine/threonine 
kinase mTOR.72 Targeting apoptosis and autophagy concur-
rently has emerged as a potential approach in the treatment 
of prostate cancer.73 Overexpression of AURKA induces 
growth-promoting and survival-promoting oncogenic signal-
ing pathways, such as the PI3K/Akt and β-catenin pathways 
in UGC cancer cells.74
In this study, ALS induced autophagy in both SKOV3 
and OVCAR4 cells, which may contribute to its anticancer 
activity. In fact, previous studies have shown the autophagy-
inducing effect of ALS in various cancer cell lines via regu-
lation of the PI3K/Akt/mTOR axis.75 In the present study, 
we also observed that the autophagy-inducing effect of ALS 
outweighed its apoptosis-inducing effect. Autophagy has a 
multifaceted role in cancer; it functions as a tumor suppressor 
at an early stage of tumor development, but can also be used 
by cancer cells as a cytoprotection mechanism to promote 
survival of established tumors.64
In general, cancer cells proliferate depending on glyco-
lysis, whereas supply of glucose and other nutrients may not 
always be sufficient. Therefore, cancer cells can often be 
exposed to an intracellular energy and/or nutrient imbalance 
and various forms of stress associated with energetic insuf-
ficiency. To cope with such metabolic stresses, cells have 
various mechanisms to sense nutrient status and to adapt to 
stressful cell conditions. These include the nutrient-signaling 
pathways regulated by AMPK and mechanistic/mTOR and 
also cellular stress responses, such as mitochondrial and 
endoplasmic reticulum stress responses, as well as autophagy. 
AMPK, the master energy sensor, is an important regulator of 
cell death under various conditions, through activation of JNK 
and p53 and inhibition of mTOR.76 In the present study, there 
was a significant activation of AMPK in response to treatment 
with ALS, which may contribute to inhibition of mTOR.
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Sirt1 is the best characterized member of the sirtuin family 
and functions as a longevity-promoting protein, playing a role 
in lifespan extension induced by caloric restriction. Sirt1 is 
an nicotinamide adenine dinucleotide (NAD+)-dependent 
histone deacetylase overexpressed in prostate, colon, breast, 
gastric, liver, and pancreatic tumors.77 Sirt1 also attenuates 
p53 and PTEN, promotes EMT, and increases cell migration, 
all of which promote carcinogenesis.77
Recently, studies have shown that Sirt1 has an important 
role in the regulation of apoptosis and autophagy. Sirt1 
deacetylates both histone and nonhistone proteins, such as 
p53 and FoxOs.78 Deacetylation of p53 and inhibition of 
p53-regulated cell death indicate that Sirt1 is a negative 
regulator of p53.78 In our study, we found that ALS signifi-
cantly increased intracellular levels of deacetylated p53 and 
decreased the expression levels of Sirt1 and PBEF. PBEF is a 
rate-limiting enzyme in the NAD+ biosynthesis pathway and 
plays an essential role in regulation of Sirt1 activation.79 Taken 
together, ALS-induced cell apoptosis and autophagy in EOC 
cells may occur via a Sirt1-mediated pathway (Figure 17).
Autophagy and apoptosis are connected both positively 
and negatively, with extensive crosstalk between the two 
processes. We have found that ALS induces both apoptosis 
and autophagy. Inhibition or induction of autophagy inhibited 
ALS-induced apoptosis in SKOV3 and OVCAR4 cells. We 
speculate that these two key processes of cell death initiated 
by ALS can be coordinated by certain important molecules, 
including p53, beclin 1, and Akt (Figure 12). ALS can induce 
apoptosis and autophagy in a coordinated manner.
EMT is an important step in the developmental process. 
Recent evidence indicates that EMT allows tumor cells 
to acquire invasive properties and to develop metastatic 
growth characteristics. Some of the transcription factors that 
are actively involved in EMT have a significant role in the 
EMT-metastasis linkage. A number of studies have reported 
that EMT-inducing transcription factors, such as Twist, 
snail, slug, and ZEB, are directly or indirectly involved in 
cancer cell metastasis through a different signaling cascades, 
including the Akt, signal transducer and activator of tran-
scription 3, MAPK, and Wnt pathways, with the ultimate 
consequence of downregulating E-cadherin and upregulating 
metastatic proteins, such as N-cadherin, vimentin, and matrix 
metalloproteinase-2.80
In the present study, ALS significantly increased the ratio 
of E-cadherin over N-cadherin, which would result in EMT 
inhibition in EOC. Further, ALS suppressed the expression 
of slug and TCF-8 in SKOV3 and OVCAR4 cells. Slug is 
a master regulator of EMT, downregulating E-cadherin by 
silencing gene expression.55 TCF8/ZEB1 functions as an 
activator of the EMT process through downregulation of 
epithelial genes.55 Moreover, ALS significantly increased 
the expression level of ZO-1 but decreased the expression 
level of vimentin. ZO-1 is required for tight junction forma-
tion and function, involving the regulation of paracellular 
permeability and maintenance of cell polarity, blocking the 
movement of transmembrane proteins between the apical 
and basolateral cell surface,81 whereas vimentin is a marker 
expressed in mesenchymal cells.55
Sirtuins are a highly conserved family of NAD+-dependent 
protein lysine-modifying enzymes, with deacetylase, adenosine 
diphosphateribosyltransferase, and other deacetylase activities. 
Mammals have seven sirtuins, namely Sirts1–7. They are key 
regulators for a wide variety of cellular and physiological 
processes, such as cell proliferation, differentiation, DNA 
damage and stress response, genome stability, cell survival, 
metabolism, energy homeostasis, organ development, aging, 
and cancer. Here we present an extensive literature review of 
the roles of mammalian sirtuins, particularly Sirt1, given that it 
is the most studied sirtuin, being involved in human epithelial, 
neuronal, hematopoietic, and mesenchymal malignancies, 
covering breast, prostate, lung, thyroid, liver, colon, gastric, 
pancreatic, ovarian, and cervical cancers, tumors of the cen-
tral nervous system, leukemia and lymphoma, and soft tissue 
sarcomas. The collective evidence suggests that sirtuins are 
involved in both promoting and suppressing tumorigenesis 
depending on cellular and molecular contexts. We discuss the 
potential use of sirtuin modulators, especially sirtuin inhibitors, 
in cancer treatment.82
It was reported that reduction of Sirt1 promoted metastasis 
of breast epithelial cells in an orthotopic model of breast cancer 
and promoted EMT and cell motility in these cells in vitro. 
Further, EMT could be induced in both breast epithelial and 
kidney epithelial cells in vitro, and this was also repressed 
by Sirt1.83 In our study, we found that ALS suppressed Sirt1 
in SKOV3 and OVCAR4 cells in a concentration-dependent 
manner (Figure 17). This result indicates that Sirt1 has a role 
in the oncogenesis of EOC and that ALS might inhibit EMT 
through a Sirt1-mediated pathway. In our study, ALS downreg-
ulated expression of PBEF/visfatin in SKOV3 and OVCAR4 
cells. PBEF/visfatin has been proposed to be involved in 
preventing apoptosis in cancer cells, and as such has received 
a great deal of attention in recent years and stimulated the 
development of specific inhibitors for treating cancer.84 
In summary, ALS preferentially bound to AURKA over 
AURKB via hydrogen bond formation, charge interactions, 
and π-π stacking interactions. ALS induced inhibition of the 
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PI3K/Akt/mTOR and p38 MAPK pathways and activation 
of AMPK, contributing to the autophagy-inducing activi-
ties of ALS. Modulation of autophagy altered basal and 
ALS-induced apoptosis in both cell lines. In addition, ALS 
suppressed EMT via regulation of E-cadherin suppressor 
with involvement of Sirt1. ALS also downregulated PBEF/
visfatin, and inhibition of PBEF/visfatin significantly 
enhanced basal and ALS-induced apoptosis and autophagy 
in both cell lines. ALS may represent a new anticancer drug 
that can kill EOC cells and prevent EMT. More studies 
are needed to reveal the underlying mechanisms and other 
potential targets of ALS in the treatment of EOC.
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